Current treatment of parotid hemangiomas

Laryngoscope

Volumn 121, Issue 8, 2011, Pages 1642-1650

  Weiss, Inanna ^a   Teresa, M O ^a   Lipari, Brian A ^a   Meyer, Lutz ^b   Berenstein, Alejandro ^a   Waner, Milton ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b ST JOSEPH KRANKENHAUS   (Germany)

Author keywords

Infantile hemangioma; parotid sclerotherapy; parotidectomy; pediatric otolaryngology; propranolol; vascular tumor

Indexed keywords

ALPHA2A INTERFERON; BLEOMYCIN; ENBUCRILATE; PREDNISOLONE; PREDNISONE; PROPRANOLOL; VINCRISTINE;

ADOLESCENT; CHILD; CLINICAL ASSESSMENT; CUSHINGOID SYNDROME; DIFFUSION WEIGHTED IMAGING; ENDOVASCULAR SCLEROTHERAPY; FEMALE; GROWTH RETARDATION; HEMANGIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOOD CHANGE; NEUROPHYSIOLOGY; OPPORTUNISTIC INFECTION; PAROTID HEMANGIOMA; PERSONALITY; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SCLEROTHERAPY; SEX RATIO; SIDE EFFECT; STEROID THERAPY; STOMACH IRRITATION; SURGICAL TECHNIQUE; TREATMENT RESPONSE; TUMOR GROWTH; WEIGHT REDUCTION;

CHILD, PRESCHOOL; FEMALE; HEMANGIOMA; HUMANS; INFANT; LASER THERAPY; MALE; PAROTID NEOPLASMS; SCLEROTHERAPY;

EID: 79960965270     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.21358     Document Type: Review

References (27)

1. Waner M, North PE, Scherer KA, Frieden IJ, Waner A, Mihm MC, Jr., The nonrandom distribution of facial hemangiomas. Arch Dermatol 2003; 139: 869-875. (Pubitemid 36898921)
2. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA,. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357-2364. (Pubitemid 24177146)
3. Bentz BG, Hughes CA, Ludemann JP, Maddalozzo J,. Masses of the salivary gland region in children. Arch Otolaryngol Head Neck Surg 2000; 126: 1435-1439.
4. Waner M, Suen JY,. Hemangiomas and vascular malformations of the head and neck. New York: J. Wiley; 1999.
5. Boon LM, MacDonald DM, Mulliken JB,. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104: 1616-1623. (Pubitemid 29510480)
6. Buckmiller LM, Francis CL, Glade RS,. Intralesional steroid injection for proliferative parotid hemangiomas. Int J Pediatr Otorhinolaryngol 2008; 72: 81-87. (Pubitemid 350198656)
7. Ezekowitz RA, Mulliken JB, Folkman J,. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-1463.
8. Blei F, Isakoff M, Deb G,. The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids. Arch Otolaryngol Head Neck Surg 1997; 123: 841-844. (Pubitemid 27338028)
9. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A,. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651. (Pubitemid 351831393)
10. Mabeta P, Pepper MS,. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 2009; 12: 81-90.
11. O TM, Alexander RE, Lando T, et al. Segmental hemangiomas of the upper airway. Laryngoscope 2009; 119: 2242-2247.
12. Baker LL, Dillon WP, Hieshima GB, Dowd CF, Frieden IJ,. Hemangiomas and vascular malformations of the head and neck: MR characterization. AJNR Am J Neuroradiol 1993; 14: 307-314. (Pubitemid 23130124)
13. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527-530. (Pubitemid 28180264)
14. Sommers Smith SK, Smith DM,. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002; 38: 298-304. (Pubitemid 35204978)
15. D'Angelo G, Lee H, Weiner RI,. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353-366. (Pubitemid 27509471)
16. Song JK, Niimi Y, Berenstein A,. Endovascular treatment of hemangiomas. Neuroimaging Clin N Am 2007; 17: 165-173. (Pubitemid 47077632)
17. Canter HI, Vargel I, Mavlll ME, Gokoz A, Erk Y,. Tissue response to N-butyl-2-cyanoacrylate after percutaneous injection into cutaneous vascular lesions. Ann Plast Surg 2002; 49: 520-526. (Pubitemid 35278542)
18. Mabeta P, Davis PF,. The mechanism of bleomycin in inducing haemangioma regression. S Afr Med J 2008; 98: 538-539.
19. Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO,. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004; 19: 766-773. (Pubitemid 38387457)
20. Saitta P, Krishnamurthy K, Brown LH,. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg 2008; 34: 1299-1313.
21. Bernat I, Grayeli AB, Esquia G, Zhang Z, Kalamarides M, Sterkers O,. Intraoperative electromyography and surgical observations as predictive factors of facial nerve outcome in vestibular schwannoma surgery. Otol Neurotol 2010; 31: 306-312.
22. Ulkatan S, Deletis V, Fernandez-Conejero I,. Central or peripheral activations of the facial nerve? J Neurosurg 2007; 106: 519-520; author reply 20.
23. Moore KL, Persaud TVN, Torchia MG,. The developing human: clinically oriented embryology. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2008.
24. Batsakis JG,. Vascular tumors of the salivary glands. Ann Otol Rhinol Laryngol 1986; 95: 649-650.
25. Greene AK, Rogers GF, Mulliken JB,. Management of parotid hemangioma in 100 children. Plast Reconstr Surg 2004; 113: 53-60. (Pubitemid 39202007)
26. Reinisch JF, Kim RY, Harshbarger RJ, Meara JG,. Surgical management of parotid hemangioma. Plast Reconstr Surg 2004; 113: 1940-1948. (Pubitemid 39201708)
27. Sainsbury DC, Kessell G, Guhan A, et al. Unexpected hyperpigmentation following intralesional bleomycin injection. J Plast Reconstr Aesthet Surg 2009; 62: e497-9.